Compare Freeport-McMoRan Inc (FCX) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs IDEXX Laboratories, Inc. — how do they compare? Freeport-McMoRan Inc trades at $68.84 (market cap $96.42B), while IDEXX Laboratories, Inc. trades at $572.92 (market cap $46.22B). The key difference: Freeport-McMoRan Inc is far larger — about 2.1× IDEXX Laboratories, Inc.'s market cap, and Freeport-McMoRan Inc pays a 0.87% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| FCX | IDXX | |
|---|---|---|
Market Cap | $96.42B | $46.22B |
Sector | Basic Materials | Health |
52-Week High | $71.73 | $766.68 |
52-Week Low | $35.34 | $526.44 |
Enterprise Value | $102.70B | $47.12B |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $69.18, down 1.92% today but maintains a bullish technical outlook with strong moving average support. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.68 exceeding expectations. Revenue growth remains stable at $25.9B, while profitability metrics show improvement with net income margin expanding to 11.38%. Recent news highlights operational strength at Grasberg mine and positive copper market tailwinds.
FCX presents a compelling investment case with analyst consensus pointing to 6.8% upside to the $73.85 price target. The company's growth initiatives and copper market exposure provide tailwinds, though investors should monitor commodity price volatility and execution risks in expansion projects. With 61% of analysts rating the stock a Buy, institutional sentiment remains positive despite recent price weakness.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
